LIFE-ME: Lifecare Achieves Major Breakthrough in the Attempt to Miniaturize the Sencell Glucose Sensor

Lifecare Achieves Major Breakthrough in the Attempt to Miniaturize the Sencell
Glucose Sensor
 
Lifecare is developing an implantable continuous glucose sensor based on its
proprietary osmotic pressure cell technology. One core element of the glucose
sensor is a pressure transducer, which translates the glucose-induced osmotic
pressure change in the measurement chamber into a transmittable electronic
signal. Until now, the size of the pressure transducer prevented further
miniaturization of the osmotic pressure chamber and of the final device.
Lifecare has partnered with cantiMED, Darmstadt, Germany, a global leader in
nanotechnology solutions, to solve the problem. Scientists from both companies
are pleased to report that the nanosensor technology has been shown in
laboratory experiments to accurately measure pressure changes derived from
substantially smaller osmotic pressure chambers. The working prototype
laboratory sensor model had only a fourth of the size of the actual version, and
further downsizing to less than a tenth is warranted based on the actual
results. 

"These findings represent a major break-through for our entire glucose sensor
development" says Lifecare Chairman of the Board Christian Saure, "We can now
continue to significantly down-size our device by miniaturizing the core
glucose-sensing element of our device with the smallest pressure sensor of the
world, which will ultimately lead to significant competitive advantages for the
final product."